One label, several different businesses
“AI healthcare stocks” is a label that gets stretched across businesses with almost nothing in common, and that is the first thing to understand before buying any of them. The category spans AI drug discovery, diagnostic imaging, clinical documentation, hospital administration, and remote monitoring. A company designing proteins with generative models has a completely different risk profile from one automating medical billing, yet both get filed under the same headline.
The promo that prompts the question here, Alexander Green’s Oxford Club “sub-$10 AI drug stock” pitch, sits squarely in the drug discovery corner. The company behind the tease, Absci, uses AI to design new medicines, and that is a very specific claim. Understanding the map matters because the valuation multiple a drug discovery company deserves is not the multiple a billing software company deserves.
The drug discovery corner
AI drug discovery is the most ambitious and the most speculative corner of the space. The promise is that machine learning can search a vastly larger space of possible drug designs and find candidates in weeks that would take traditional screening years. The reality is that discovery is only the first step, and every candidate still has to survive years of clinical trials before it earns a dollar of revenue.
Absci illustrates the model. It converts proteins into a digital form its generative AI can analyze, and it has validated the platform with real partners: Merck, AstraZeneca, and Eli Lilly are all on the roster. Its lead asset is an antibody for pattern hair loss with data due in the second half of 2026. That is the honest shape of an AI drug discovery bet: a real platform, real partners, and a binary clinical readout in front of it. We compare the drug discovery business models in our AI biotech stocks piece.
The diagnostics and imaging corner
The diagnostics corner is a different trade entirely. AI is genuinely good at reading medical images, and the companies that build those tools sell them to hospitals and clinics as software. Their revenue is recurring and their risk is regulatory approval and adoption, not a clinical binary. That makes them more like software businesses than biotech, and they should be valued as such.
The distinction matters because the promo hype cycles blur it. A pitch about “AI in healthcare” often borrows the promise of the drug discovery story, the “this changes everything” energy, and quietly attaches it to a much tamer software business, or vice versa. Our medical AI stocks explainer walks through the supply chain that serves that software side.
The administrative corner, and why it is different
The least glamorous corner is administration: AI that writes clinical notes, codes claims, and manages schedules. These companies are growing fast because the cost savings are immediate and measurable, but their competitive advantage is usually thin. A billing tool can be swapped for a competitor’s in a way a drug platform cannot, which is why the multiples in this corner look more like software than biotech.
None of this means one corner is a better investment than another. It means the first question to ask is which corner you are actually in. A drug discovery stock is a bet on science and clinical data. A diagnostic stock is a bet on regulatory approval and hospital adoption. An administrative stock is a bet on cost savings and retention. They all trade under “AI healthcare,” but they are not the same risk.
The test that sorts them out
The fastest way to sort AI healthcare stocks is to look at what the company actually sells. If it sells a software subscription to a hospital, it is a software business. If it licenses drug candidates to pharma, it is a biotech business. If it runs its own clinical trials, it is a biotech business with a balance sheet to watch. The name on the label matters far less than the thing the company does, and the thing the company does is visible in its revenue line and its cash burn.
Absci, for the record, is the biotech kind: it earns milestone payments and strategic investments while it develops drugs, and its near-term value turns on a clinical readout. That is a perfectly legitimate category to own, but it is a category, not a catch-all, and the first discipline in AI healthcare investing is knowing which category you are in. The label is where the conversation starts; the revenue line is where it ends. For the sector map, see our AI drug discovery companies guide.
Ready to see the research? Click here to access Alexander Green’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.